MET and neoplasm: Among them, specifically targeting the downstream mediators of c-Met involved in tumor progression is a promising method, including the Grb2 SH2 domain, Src, MAPK, STAT3, Shp2 (Liu et al., 2018), and Fak (Jo et al., 2015).